Clinical trials: Influenza in Humans
Influenza
Adaptive Immune Responses and Repertoire in Influenza Vaccination and Infection (SLVP031)
The purpose of this study is provide a better understanding of the adaptive immune response to the licensed flu vaccines. The investigators hope the information learned from this study will help identify and describe important…
- Trial name
- NCT03028987
- Testing
- Fluzone®, FluMist®
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Stanford University
Influenza
A Dose Ranging Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' GSK1557484A Vaccine in Children 6 to Less Than 36 Months of Age
The purpose of this study is to assess the safety and immunogenicity of different formulations of GSK Biologicals' influenza candidate vaccine GSK1557484A, in children 6-35 months of age.
- Trial name
- NCT02719743
- Testing
- Influenza A (H5N1) Virus monovalent vaccine (GSK1557484A).
- Where
- 7 sites in Taiwan, Thailand
- Volunteers
- 185 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in Children
The purpose of this study is to evaluate the efficacy, immunogenicity and safety of GSK Biologicals' influenza candidate vaccine GSK2321138A when compared to non-influenza vaccine comparators in children 6 to 35 months of age.
- Trial name
- NCT01439360
- Testing
- Quadrivalent seasonal influenza vaccine(Flu D-QIV) GSK2321138A, Havrix Junior, Prevenar 13
- Where
- 103 sites in Bangladesh, Belgium and 11 more
- Volunteers
- 12,046 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Safety Study of CSL Limited's Influenza Virus Vaccine in the Paediatric Population Aged >= 6 Months to < 18 Years
A Phase IV, Open Label, Multi-Centre Study to Evaluate the Safety and Tolerability Profile of CSL Limited's Influenza Virus Vaccine in a Paediatric Population Aged >= 6 Months to < 18 Years
- Trial name
- NCT00825162
- Testing
- CSL Limited Influenza Virus Vaccine
- Where
- 7 sites in Australia
- Volunteers
- 1,992 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza
Inactivated Influenza Vaccine Delivered by Microneedle Patch or by Hypodermic Needle
Title: A Phase I Study of The Safety, Reactogenicity, Acceptability and Immunogenicity of Inactivated Influenza Vaccine Delivered either by Microneedle Patch or by Hypodermic Needle.
- Trial name
- NCT02438423
- Testing
- Inactivated influenza vaccine
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Mark Prausnitz
Influenza, Human
Enhanced Safety Surveillance of GlaxoSmithKline's (GSK's) Quadrivalent Seasonal Influenza Vaccines During the 2018/19 Influenza Season
The purpose of this study is to comply with the European Medicines Agency (EMA) guidance on enhanced safety surveillance for seasonal influenza vaccines in the European Union (EU) and aims to assess adverse events of interest…
- Trial name
- NCT03688620
- Testing
- Passive enhanced safety surveillance
- Where
- 9 sites in Belgium, Germany and 1 more
- Volunteers
- 1,060 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 65 Years of Age and Older
The purpose of this placebo controlled study is to evaluate the safety and immunogenicity of different formulations of GSK Biologicals H7N1 influenza vaccine in subjects 65 years of age and older.
- Trial name
- NCT01949090
- Testing
- Investigational H7N1 vaccine GSK2789869A
- Where
- 8 sites in United States, Canada
- Volunteers
- 363 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Moderate to Severe Asthma
Study to Assess the Effect of Tezepelumab on the Immune Response to Influenza Vaccination in Participants With Asthma
This is a Phase 3b, multicenter, randomized, double-blind, parallel group, placebo-controlled study designed to investigate the potential effect of tezepelumab (210 mg subcutaneous [SC] every 4 weeks [Q4W]) on antibody responses…
- Trial name
- VECTOR (NCT05062759)
- Testing
- Tezepelumab
- Where
- 15 sites in United States
- Volunteers
- 70 people
- Sponsor
- AstraZeneca
Immunization; Infection
Phase 3 Study of BK1310 in Healthy Infants
The purpose of this study is to: (cohort 1) evaluate safety and immunogenicity (Haemophilus influenzae type b, Hib) of BK1310. (cohort 2) evaluate efficacy and safety of BK1310 using ActHIB® and Tetrabik as a control in healthy…
- Trial name
- NCT02992925
- Testing
- DPT-IPV-Hib-High（Combined Vaccine）, DPT-IPV-Hib-Low（Combined Vaccine）, Hib vaccine
- Where
- 3 sites in Japan
- Volunteers
- 370 people, healthy volunteers welcome
- Sponsor
- Tanabe Pharma Corporation
Healthy
A Study to Evaluate the Shedding and Safety of Trivalent Influenza Virus Vaccine Live, Intranasal in Infants and Young Children
Open label, single arm, multicenter study of the shedding and safety of a single dose of trivalent, influenza virus vaccine live, intranasal in children 6 to < 60 months of age, with 28-day shedding follow-up and 180-day safety…
- Trial name
- NCT00344305
- Testing
- Trivalent influenza virus vaccine live, intranasal
- Where
- 16 sites in United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Influenza A
Study of Efficacy and Safety of IV VIS410 Plus Oseltamivir Versus Oseltamivir in Hospitalized Adults With Influenza A
This study is to compare the efficacy and safety of VIS410 in combination with oseltamivir vs oseltamivir alone in severely ill subjects with influenza A infection requiring oxygen support.
- Trial name
- NCT03040141
- Testing
- Low dose of VIS410, High dose of VIS410
- Where
- 114 sites in United States, Australia and 18 more
- Volunteers
- 89 people
- Sponsor
- Visterra, Inc.
Influenza
Assess Safety and Immunogenicity of A/H5 Inactivated Monovalent Influenza Vaccines at Different Antigen Dose Levels Adjuvanted With AS03 or MF59
This BARDA-sponsored, randomized, double-blind, phase 2 study is designed to assess safety and immunogenicity of A/H5 inactivated monovalent influenza vaccines at different antigen dose levels adjuvanted with AS03 or MF59.
- Trial name
- NCT06560151
- Testing
- 3.75 µg H5N8 antigen plus full dose AS03A, 7.5 µg H5N8 antigen plus full dose AS03A, 15 µg H5N8 antigen plus full dose AS03A
- Where
- 20 sites in United States
- Volunteers
- 1,380 people, healthy volunteers welcome
- Sponsor
- Biomedical Advanced Research and Development Authority
MAJOR DEPRESSIVE DISORDER
Influenza Challenge in Mood Disorders
The aim of this project is to evaluate the efficacy of the influenza vaccine in individuals with major depressive disorder (MDD) as well as to elucidate the nature of the immunological abnormalities in MDD using a…
- Trial name
- NCT02415166
- Testing
- INFLUENZA VACCINE
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Laureate Institute for Brain Research, Inc.
Influenza, Human
A Study to Evaluate a Modified RNA Vaccine Against Influenza in Adults 18 Years of Age or Older
This is a Phase 3, randomized, observer-blinded study to evaluate the efficacy, safety, tolerability, and immunogenicity of a single dose of a quadrivalent influenza modRNA vaccine compared to licensed inactivated influenza…
- Trial name
- NCT05540522
- Testing
- Quadrivalent influenza modRNA vaccine, Quadrivalent influenza vaccine
- Where
- 321 sites in United States, Argentina and 4 more
- Volunteers
- 45,789 people, healthy volunteers welcome
- Sponsor
- Pfizer
Influenza
A Phase III, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Uncomplicated Influenza
Trial to evaluate efficacy and safety of nitazoxanide (NTZ) in the treatment of uncomplicated influenza.
- Trial name
- NCT03336619
- Testing
- Nitazoxanide
- Where
- 38 sites in United States, Australia and 1 more
- Volunteers
- 1,030 people
- Sponsor
- Romark Laboratories L.C.
Influenza
Safety and Reactogenicity of FluBlok and Comparison of Immunogenicity, Efficacy and Effectiveness Against TIV
The purpose of this study was to evaluate and compare the safety, reactogenicity, immunogenicity, relative efficacy and effectiveness of FluBlok to a licensed trivalent influenza vaccine (TIV)in healthy adults age 50-64 years.
- Trial name
- NCT00539864
- Testing
- FluBlok Influenza Vaccination, TIV (Fluzone) Influenza Vaccination
- Where
- 5 sites in United States
- Volunteers
- 602 people, healthy volunteers welcome
- Sponsor
- Protein Sciences Corporation
Influenza
Immunogenicity and Safety Study of an Investigational Influenza (H1N1 Influenza Virus) Vaccine in Adults
The objective of this study is to evaluate the immunogenicity and safety of GSK Biologicals' investigational vaccine GSK2340272A in adults aged 18 to 60 years.
- Trial name
- NCT00989287
- Testing
- GSK2340272A, GSK2340269A
- Where
- Belgium
- Volunteers
- 131 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Respiratory Viral Infection
Pilot of Cohort of Households for Influenza Monitoring and Evaluation in Seattle
This study will evaluate a home-based approach to influenza infection control, using prepositioned home-based influenza self-test kits, telemedicine services, and rapid delivery of Xofluza (Baloxavir marboxil) for administration…
- Trial name
- pCHIMES (NCT04141930)
- Testing
- Baloxavir Marboxil
- Where
- United States
- Volunteers
- 481 people, healthy volunteers welcome
- Sponsor
- University of Washington
Influenza
Study of Live, Attenuated Influenza Vaccination in Preterm and Full-Term Infants
Severe influenza respiratory disease is increasingly recognized in children. Influenza hospitalization rates in high-risk infants, such as premature infants, are increased some five-fold over rates in other children.
- Trial name
- NCT01194297
- Testing
- Live attenuated influenza vaccine, Inactivated influenza vaccine
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Influenza
The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults
The purpose of this study is to evaluate the preventative antiviral activity of CD388, as compared to saline placebo, when administered as a single dose to healthy adult participants in a human viral challenge model of influenza.
- Trial name
- NCT05523089
- Testing
- CD388
- Where
- United Kingdom
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)